Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.
Клиническое исследование I фазыСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tap William D, Cote Gregory M, Burris Howard, Gore Lia, Elias Anthony, Beeram Murali, Conley Anthony P, Gianolio Diego A, Qu Zhe, Pandya Susan, Trent Jonathan C
Аннотация
PURPOSE: A phase I study demonstrated that ivosidenib, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, showed manageable toxicity and durable disease control in patients with mIDH1 conventional chondrosarcoma (CS). In this study, we present long-term follow-up data on the safety and clinical activity of ivosidenib in patients with mIDH1 conventional CS from this phase I study.
PATIENTS AND METHODS: This phase I, open-label, dose-escalation, and expansion study assessed ivosidenib monotherapy in patients with advanced mIDH1 solid tumors, including CS. An ivosidenib dose of 500 mg/day was identified in the dose-escalation phase and used for the expansion phase. The primary outcome was safety and tolerability. Secondary outcomes included objective response rate and progression-free survival. The database lock date for this analysis was March 18, 2024.
RESULTS: Of 168 patients with advanced mIDH1 solid tumors receiving ivosidenib in this study, 21 patients had CS, of which 13 had conventional histology. Six (46.2%), 4 (30.8%), and 3 (23.1%) patients with conventional CS continued ivosidenib treatment for >1 year, >6 years, and >7 years, respectively. Of the 21 patients with CS, 71.4% and 28.6% had treatment-related and serious adverse events, respectively, but no serious adverse events were considered related to ivosidenib. The objective response rate for patients with conventional CS was 23.1%, and the median duration of response was 53.5 months. The median progression-free survival of patients with conventional CS treated with ivosidenib was 7.4 months.
CONCLUSIONS: Ivosidenib demonstrated long-term disease control and manageable toxicity for some patients with mIDH1 conventional CS and is under further investigation (NCT06127407).
PATIENTS AND METHODS: This phase I, open-label, dose-escalation, and expansion study assessed ivosidenib monotherapy in patients with advanced mIDH1 solid tumors, including CS. An ivosidenib dose of 500 mg/day was identified in the dose-escalation phase and used for the expansion phase. The primary outcome was safety and tolerability. Secondary outcomes included objective response rate and progression-free survival. The database lock date for this analysis was March 18, 2024.
RESULTS: Of 168 patients with advanced mIDH1 solid tumors receiving ivosidenib in this study, 21 patients had CS, of which 13 had conventional histology. Six (46.2%), 4 (30.8%), and 3 (23.1%) patients with conventional CS continued ivosidenib treatment for >1 year, >6 years, and >7 years, respectively. Of the 21 patients with CS, 71.4% and 28.6% had treatment-related and serious adverse events, respectively, but no serious adverse events were considered related to ivosidenib. The objective response rate for patients with conventional CS was 23.1%, and the median duration of response was 53.5 months. The median progression-free survival of patients with conventional CS treated with ivosidenib was 7.4 months.
CONCLUSIONS: Ivosidenib demonstrated long-term disease control and manageable toxicity for some patients with mIDH1 conventional CS and is under further investigation (NCT06127407).